<DOC>
	<DOC>NCT00061022</DOC>
	<brief_summary>This study will determine if NXY-059 will improve recovery from an acute stroke. The study is designed to look at both overall recovery and recovery of motor function, for example muscle strengthen and coordination.</brief_summary>
	<brief_title>Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Ischemic Attack, Transient</mesh_term>
	<mesh_term>Disufenton sodium</mesh_term>
	<criteria>Males and females Acute ischemic stroke with limb weakness Onset of symptoms within 6 hours Full functional independence prior to the present stroke Unconsciousness Subjects who are unlikely to complete the infusion of investigational product and/or are unlikely to undergo active medical management during that period due to a severe clinical condition. Severe illness with life expectancy less than 6 months. Known severe kidney disorder. Current known alcohol or illicit drug abuse or dependence. Pregnant or breastfeeding. Treatment with acetazolamide and methotrexate is not permitted during the infusion Participation in a previous clinical study within 30 days. Meets all other exclusion criteria.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Stroke</keyword>
	<keyword>cerebral vascular accident</keyword>
	<keyword>CVA</keyword>
	<keyword>Ischemia</keyword>
	<keyword>Hemorrhage</keyword>
	<keyword>TIA</keyword>
	<keyword>Transient Ischemic Attack</keyword>
	<keyword>Brain Attack</keyword>
	<keyword>Cataplexy</keyword>
</DOC>